Get the Stockscreener App
94.15
4.86%
4.36
Glaukos Corporation stock is traded at $94.15, with a volume of 688.01K.
It is up +4.86% in the last 24 hours and down -2.29% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$89.79
Open:
$90.79
24h Volume:
688.01K
Relative Volume:
0.71
Market Cap:
$5.40B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-31.81
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
+4.77%
1M Performance:
-2.29%
6M Performance:
-25.21%
1Y Performance:
-27.61%
1-Day Range:
$89.48
$94.71
1-Week Range:
$88.21
$94.71
52-Week Range:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
94.15 | 5.13B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Glaukos Corporation Volume Confirms Breakout — Analysts Bullish2025 Market Outlook & Precise Entry and Exit Recommendations - classian.co.kr
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised - MSN
Why Glaukos Corporation stock attracts strong analyst attentionJuly 2025 Intraday Action & Daily Price Action Insights - beatles.ru
Institutional Tools Highlight Unusual Flow in Glaukos CorporationMarket Growth Report & Capital Efficiency Focused Ideas - 선데이타임즈
Will breakout in Glaukos Corporation lead to full recovery2025 Market WrapUp & Free Real-Time Market Sentiment Alerts - Newser
Will a bounce in Glaukos Corporation offer an exitWeekly Trade Recap & Fast Entry High Yield Tips - Newser
Published on: 2025-08-16 03:30:21 - Newser
Is Glaukos Corporation still worth holding after the dipTrade Volume Report & Low Risk Profit Maximizing Plans - Newser
How to escape a deep drawdown in Glaukos Corporation2025 Price Targets & Expert Curated Trade Setup Alerts - Newser
Published on: 2025-08-16 01:20:21 - Newser
What analysts say about Glaukos Corporation stock outlookJuly 2025 Review & Daily Chart Pattern Signals - Newser
Midday Stock Roundup: ICU Medical Soars, Willdan Group Down - Orange County Business Journal
Glaukos Corporation Hits Price Floor — Bounce IncomingWeekly Market Summary & Fast Exit Strategy with Risk Control - theviewers.co.kr
Glaukos Highlights Innovation in Recent Investor Presentation - TipRanks
RSI Reset May Fuel Rebound in Glaukos CorporationStock Surge & AI Powered Buy and Sell Recommendations - beatles.ru
Glaukos Corporation (NYSE:GKOS) Shares Sold by Vanguard Group Inc. - Defense World
Glaukos Corporation shares rise 1.32% intraday after investor presentation in August 2024. - AInvest
RSI + MACD Show Convergence for Glaukos Corporation2025 Growth vs Value & High Accuracy Trade Alerts - sundaytimes.kr
Glaukos Emphasizes Innovation in Recent Investor Presentation: A Closer Look - AInvest
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Glaukos (GKOS) - The Globe and Mail
Glaukos Announces Participation in Wells Fargo Healthcare Conference | GKOS Stock News - GuruFocus
Glaukos Announces Participation in Wells Fargo Healthcare Conference - MarketScreener
Will Glaukos Corporation Reverse From Oversold ConditionsAlpha Focused Technical Trade Signals Gain Attention - metal.it
Institutional scanner results for Glaukos CorporationWealth Accumulation Outlook for Safe Investors - Newser
Glaukos : Investor Presentation August 2024 - MarketScreener
What Glaukos (GKOS)'s Strong Q2 Results and Upgraded Guidance Mean For Shareholders - simplywall.st
Glaukos Corporation stock trendline breakdownFree Optimized Watchlist With Daily Adjustments - Newser
Glaukos shares fall 41% after InvestingPro’s February overvaluation alert By Investing.com - Investing.com Nigeria
Glaukos Corporation (NYSE:GKOS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Glaukos (GKOS) Narrows Loss and Lifts Full-Year Outlook After Second-Quarter Results – What's Changed - simplywall.st
Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Call Transcript - MSN
What catalysts could drive Glaukos Corporation stock higher in 2025Access high-quality stock research instantly - Jammu Links News
What is the dividend policy of Glaukos Corporation stockExceptional growth trajectory - Jammu Links News
How strong is Glaukos Corporation company’s balance sheetCapitalize on market momentum for big wins - Jammu Links News
What analysts say about Glaukos Corporation stockMaximize portfolio growth with expert advice - Jammu Links News
Is Glaukos Corporation a good long term investmentUnlock expert trading strategies for growth - Jammu Links News
What markets is MBIO expanding into Is Glaukos Corporation stock a good long term investment optionFree Trend-Following Techniques - Jammu Links News
Press Release: Glaukos Announces Second Quarter 2025 Financial Results - 富途牛牛
Glaukos Q2 Revenue Up 30%: Strong Adoption of Glaucoma Products in US and Global Expansion - AInvest
Glaukos (GKOS) Maintains Rating, Raises Price Target to $92. - AInvest
Glaukos Corporation's Q2 Earnings: Analysts Reassess Growth Prospects - AInvest
Glaukos Corporation (NYSE:GKOS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo.co
Glaukos Corporation (NYSE:GKOS) Q2 2025 Earnings Call Transcript - Insider Monkey
Glaukos (GKOS) Q2 Revenue Jumps 30% - Nasdaq
Glaukos Corp. Reports Record Growth Amid Challenges - TipRanks
Forecasting Glaukos Corporation price range with options dataOversold Recovery Opportunity Stocks Attract Buyers - metal.it
What is the risk reward ratio of investing in Glaukos Corporation stockSmart Portfolio Watchlist To Watch Now - Jammu Links News
Glaukos price target raised to $118 from $117 at BTIG - TipRanks
Mizuho lowers Glaukos stock price target to $130 on mixed outlook - Investing.com Nigeria
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Glaukos Corporation Stock (GKOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER |
Mar 25 '25 |
Sale |
106.84 |
1,520 |
162,399 |
53,431 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):